Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.

Reardon DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM, Cruickshank S, Vitale L, He Y, Green JA, Yellin MJ, Turner CD, Keler T, Davis TA, Sampson JH; ReACT trial investigators.

Clin Cancer Res. 2020 Feb 7. doi: 10.1158/1078-0432.CCR-18-1140. [Epub ahead of print]

PMID:
32034072
2.

Addressing Misdiagnosis of Optic Nerve Sheath Meningiomas.

Kalen BD, Hess RA, Abi-Aad KR, Welz ME, Patra DP, Sharma A, Mrugala MM, Porter AB, Bendok BR, Acierno MD.

World Neurosurg. 2020 Jan;133:419-420. doi: 10.1016/j.wneu.2019.10.122. No abstract available.

PMID:
31881557
3.

Clinical evaluation of fitness to drive in patients with brain metastases.

Valencia-Sanchez C, Gorelkin VC, Mrugala MM, Sharma A, Vora SA, Ashman JB, Daniels TB, Halyard MY, Rule WG, Zhang N, Butterfield RJ, Schild SE, Porter AB.

Neurooncol Pract. 2019 Dec;6(6):484-489. doi: 10.1093/nop/npz027. Epub 2019 Jul 3.

PMID:
31832219
4.

Expanding the Spectrum of Radiation Necrosis After Stereotactic Radiosurgery (SRS) for Intracranial Metastases From Lung Cancer: A Retrospective Review.

Sharma A, Mountjoy LJ, Butterfield RJ, Zhang N, Ross HJ, Schild SE, Sio TT, Daniels TB, Paripati HR, Mrugala MM, Vora SA, Patel NP, Zimmerman RS, Ashman JB, Porter AB.

Am J Clin Oncol. 2020 Feb;43(2):128-132. doi: 10.1097/COC.0000000000000642.

PMID:
31764021
5.

Neuro-oncologists have spoken - the role of bevacizumab in the inpatient setting. A clinical and economic conundrum.

Sharma A, Low J, Mrugala MM.

Neurooncol Pract. 2019 Jan;6(1):30-36. doi: 10.1093/nop/npy011. Epub 2018 Apr 19.

6.

ENvironmental Dynamics Underlying Responsive Extreme Survivors (ENDURES) of Glioblastoma: A Multidisciplinary Team-based, Multifactorial Analytical Approach.

Johnston SK, Whitmire P, Massey SC, Kumthekar P, Porter AB, Raghunand N, Gonzalez-Cuyar LF, Mrugala MM, Hawkins-Daarud A, Jackson PR, Hu LS, Sarkaria JN, Wang L, Gatenby RA, Egan KM, Canoll P, Swanson KR; ENDURES consortium.

Am J Clin Oncol. 2019 Aug;42(8):655-661. doi: 10.1097/COC.0000000000000564.

PMID:
31343422
7.

Phase II Study of Systemic High-dose Methotrexate and Intrathecal Liposomal Cytarabine for Treatment of Leptomeningeal Carcinomatosis From Breast Cancer.

Mrugala MM, Kim B, Sharma A, Johnson N, Graham C, Kurland BF, Gralow J.

Clin Breast Cancer. 2019 Oct;19(5):311-316. doi: 10.1016/j.clbc.2019.04.004. Epub 2019 Apr 18.

PMID:
31175053
8.

Accurate Patient-Specific Machine Learning Models of Glioblastoma Invasion Using Transfer Learning.

Hu LS, Yoon H, Eschbacher JM, Baxter LC, Dueck AC, Nespodzany A, Smith KA, Nakaji P, Xu Y, Wang L, Karis JP, Hawkins-Daarud AJ, Singleton KW, Jackson PR, Anderies BJ, Bendok BR, Zimmerman RS, Quarles C, Porter-Umphrey AB, Mrugala MM, Sharma A, Hoxworth JM, Sattur MG, Sanai N, Koulemberis PE, Krishna C, Mitchell JR, Wu T, Tran NL, Swanson KR, Li J.

AJNR Am J Neuroradiol. 2019 Mar;40(3):418-425. doi: 10.3174/ajnr.A5981. Epub 2019 Feb 28.

9.

Next-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Leptomeningeal Carcinomatosis: Review of 2 Cases.

Grimsrud KW, Mrugala MM.

Neurologist. 2019 Mar;24(2):59-61. doi: 10.1097/NRL.0000000000000220.

PMID:
30817492
10.

The Use of Recombinant Poliovirus for the Treatment of Recurrent Glioblastoma Multiforme.

Abi-Aad KR, Turcotte EL, Welz ME, Krishna C, Mrugala MM, Porter AB, Vora SA, Bendok BR.

World Neurosurg. 2019 Jan 22. pii: S1878-8750(19)30147-0. doi: 10.1016/j.wneu.2019.01.050. [Epub ahead of print] No abstract available.

PMID:
30682513
11.

Disseminated High-grade Glioma in a Long-term Survivor of Medulloblastoma: Implications and Management of Radiation-induced Malignancies.

Porter AB, Sio TT, Nelson KD, Raghunathan A, Bendok BR, Mrugala MM.

Neurologist. 2018 Nov;23(6):191-193. doi: 10.1097/NRL.0000000000000199.

PMID:
30379742
12.

A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling.

Wenger C, Miranda PC, Salvador R, Thielscher A, Bomzon Z, Giladi M, Mrugala MM, Korshoej AR.

IEEE Rev Biomed Eng. 2018;11:195-207. doi: 10.1109/RBME.2017.2765282. Epub 2018 Feb 13. Review.

PMID:
29993870
13.

Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice.

Lukas RV, Mrugala MM.

Neurooncol Pract. 2017 Dec;4(4):209-219. doi: 10.1093/nop/npw016. Epub 2016 Aug 26. Review.

14.

NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.

Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A.

J Natl Compr Canc Netw. 2017 Nov;15(11):1331-1345. doi: 10.6004/jnccn.2017.0166.

PMID:
29118226
15.

Tumor Treating Fields in Neuro-Oncological Practice.

Mrugala MM, Ruzevick J, Zlomanczuk P, Lukas RV.

Curr Oncol Rep. 2017 Aug;19(8):53. doi: 10.1007/s11912-017-0611-8. Review.

PMID:
28664468
16.

Management of Leptomeningeal Disease From Solid Tumors.

Lukas RV, Buerki R, Mrugala MM.

Oncology (Williston Park). 2016 Aug;30(8):724-30. Review. No abstract available.

17.

Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience.

Ly KI, Crew LL, Graham CA, Mrugala MM.

Oncol Lett. 2016 May;11(5):3471-3476. Epub 2016 Mar 30.

18.

Addendum to 'A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET'.

Rockne RC, Trister AD, Jacobs J, Hawkins-Daarud AJ, Neal ML, Hendrickson K, Mrugala MM, Rockhill JK, Kinahan P, Krohn KA, Swanson KR.

J R Soc Interface. 2015 Nov 6;12(112). pii: 20150927. doi: 10.1098/rsif.2015.0927. No abstract available.

PMID:
26577597
Free PMC Article
19.

Central Nervous System Cancers, Version 1.2015.

Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Lawson R, Loeffler JS, Lovely MP, Moots PL, Mrugala MM, Newton HB, Parney I, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran D, Tran N, Vrionis FD, Weiss S, Wen PY, McMillian N, Engh AM.

J Natl Compr Canc Netw. 2015 Oct;13(10):1191-202.

PMID:
26483059
20.

Improvement in Visual Fields After Treatment of Intracranial Meningioma With Bevacizumab.

Ly KI, Hamilton SR, Rostomily RC, Rockhill JK, Mrugala MM.

J Neuroophthalmol. 2015 Dec;35(4):382-6. doi: 10.1097/WNO.0000000000000253.

PMID:
26049681
21.

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH.

Neuro Oncol. 2015 Jun;17(6):854-61. doi: 10.1093/neuonc/nou348. Epub 2015 Jan 13.

22.

A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using 18F-FMISO-PET.

Rockne RC, Trister AD, Jacobs J, Hawkins-Daarud AJ, Neal ML, Hendrickson K, Mrugala MM, Rockhill JK, Kinahan P, Krohn KA, Swanson KR.

J R Soc Interface. 2015 Feb 6;12(103). pii: 20141174. doi: 10.1098/rsif.2014.1174. Erratum in: J R Soc Interface. 2015 Nov 6;12(112). pii: 20150927. doi: 10.1098/rsif.2015.0927.

23.

Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.

Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Moots PL, Mrugala MM, Newton HB, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran D, Tran N, Vrionis FD, Wen PY, McMillian NR, Ho M.

J Natl Compr Canc Netw. 2014 Nov;12(11):1517-23.

24.

Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).

Mrugala MM, Engelhard HH, Dinh Tran D, Kew Y, Cavaliere R, Villano JL, Annenelie Bota D, Rudnick J, Love Sumrall A, Zhu JJ, Butowski N.

Semin Oncol. 2014 Oct;41 Suppl 6:S4-S13. doi: 10.1053/j.seminoncol.2014.09.010. Epub 2014 Sep 16. Erratum in: Semin Oncol. 2015 Jun;42(3):e33-43.

25.

Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.

Adair JE, Johnston SK, Mrugala MM, Beard BC, Guyman LA, Baldock AL, Bridge CA, Hawkins-Daarud A, Gori JL, Born DE, Gonzalez-Cuyar LF, Silbergeld DL, Rockne RC, Storer BE, Rockhill JK, Swanson KR, Kiem HP.

J Clin Invest. 2014 Sep;124(9):4082-92. doi: 10.1172/JCI76739. Epub 2014 Aug 8.

26.

Invasion and proliferation kinetics in enhancing gliomas predict IDH1 mutation status.

Baldock AL, Yagle K, Born DE, Ahn S, Trister AD, Neal M, Johnston SK, Bridge CA, Basanta D, Scott J, Malone H, Sonabend AM, Canoll P, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR.

Neuro Oncol. 2014 Jun;16(6):779-86. doi: 10.1093/neuonc/nou027.

27.

A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.

Raizer JJ, Grimm SA, Rademaker A, Chandler JP, Muro K, Helenowski I, Rice L, McCarthy K, Johnston SK, Mrugala MM, Chamberlain M.

J Neurooncol. 2014 Mar;117(1):93-101. doi: 10.1007/s11060-014-1358-9. Epub 2014 Jan 22.

PMID:
24449400
28.

Toward patient-specific, biologically optimized radiation therapy plans for the treatment of glioblastoma.

Corwin D, Holdsworth C, Rockne RC, Trister AD, Mrugala MM, Rockhill JK, Stewart RD, Phillips M, Swanson KR.

PLoS One. 2013 Nov 12;8(11):e79115. doi: 10.1371/journal.pone.0079115. eCollection 2013.

29.

Central nervous system cancers.

Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Maor MH, Moots PL, Morrison T, Mrugala MM, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK Jr, Tran D, Tran N, Vrionis FD, Wen PY, McMillian N, Ho M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Sep 1;11(9):1114-51.

30.
31.

From patient-specific mathematical neuro-oncology to precision medicine.

Baldock AL, Rockne RC, Boone AD, Neal ML, Hawkins-Daarud A, Corwin DM, Bridge CA, Guyman LA, Trister AD, Mrugala MM, Rockhill JK, Swanson KR.

Front Oncol. 2013 Apr 2;3:62. doi: 10.3389/fonc.2013.00062. eCollection 2013.

32.

Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article.

Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan Fu B, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, Wen PY, Chen CC, Carter B, Lee JW, Kesari S.

J Neurosurg. 2013 Jun;118(6):1183-7. doi: 10.3171/2013.1.JNS12397. Epub 2013 Mar 1.

PMID:
23451905
33.

Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression.

Neal ML, Trister AD, Ahn S, Baldock A, Bridge CA, Guyman L, Lange J, Sodt R, Cloke T, Lai A, Cloughesy TF, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR.

Cancer Res. 2013 May 15;73(10):2976-86. doi: 10.1158/0008-5472.CAN-12-3588. Epub 2013 Feb 11.

34.

Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric.

Neal ML, Trister AD, Cloke T, Sodt R, Ahn S, Baldock AL, Bridge CA, Lai A, Cloughesy TF, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR.

PLoS One. 2013;8(1):e51951. doi: 10.1371/journal.pone.0051951. Epub 2013 Jan 23.

35.

Carboplatin and bevacizumab for recurrent malignant glioma.

Mrugala MM, Crew LK, Fink JR, Spence AM.

Oncol Lett. 2012 Nov;4(5):1082-1086. Epub 2012 Aug 1.

36.

Chemoprotection in glioblastoma therapy: reality or a dream?

Mrugala MM, Adair J, Kiem HP.

CNS Oncol. 2012 Sep;1(1):11-4. doi: 10.2217/cns.12.11. No abstract available.

37.

Extended survival of glioblastoma patients after chemoprotective HSC gene therapy.

Adair JE, Beard BC, Trobridge GD, Neff T, Rockhill JK, Silbergeld DL, Mrugala MM, Kiem HP.

Sci Transl Med. 2012 May 9;4(133):133ra57. doi: 10.1126/scitranslmed.3003425.

38.

Outside the box--novel therapeutic strategies for glioblastoma.

Mrugala MM, Adair JE, Kiem HP.

Cancer J. 2012 Jan-Feb;18(1):51-8. doi: 10.1097/PPO.0b013e318243f785. Review.

PMID:
22290258
39.

Temozolomide: Expanding its role in brain cancer.

Mrugala MM, Adair J, Kiem HP.

Drugs Today (Barc). 2010 Nov;46(11):833-46. doi: 10.1358/dot.2010.46.11.1549024. Review.

PMID:
21225022
40.

Genetic determinants of hearing loss associated with vestibular schwannomas.

Stankovic KM, Mrugala MM, Martuza RL, Silver M, Betensky RA, Nadol JB Jr, Stemmer-Rachamimov AO.

Otol Neurotol. 2009 Aug;30(5):661-7. doi: 10.1097/MAO.0b013e3181a66ece.

PMID:
19546833
41.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Mrugala MM.

Neurology. 2009 Feb 24;72(8):773; author reply 773-4. No abstract available.

PMID:
19248218
42.

Insights into the biology of primary central nervous system lymphoma.

Mrugala MM, Rubenstein JL, Ponzoni M, Batchelor TT.

Curr Oncol Rep. 2009 Jan;11(1):73-80. Review.

43.

High-dose methotrexate for elderly patients with primary CNS lymphoma.

Zhu JJ, Gerstner ER, Engler DA, Mrugala MM, Nugent W, Nierenberg K, Hochberg FH, Betensky RA, Batchelor TT.

Neuro Oncol. 2009 Apr;11(2):211-5. doi: 10.1215/15228517-2008-067. Epub 2008 Aug 29.

44.

Mechanisms of disease: temozolomide and glioblastoma--look to the future.

Mrugala MM, Chamberlain MC.

Nat Clin Pract Oncol. 2008 Aug;5(8):476-86. doi: 10.1038/ncponc1155. Epub 2008 Jun 10. Review.

PMID:
18542116
45.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK.

Cancer Cell. 2007 Jan;11(1):83-95.

46.

Peripheral and cranial nerve sheath tumors.

Mrugala MM, Batchelor TT, Plotkin SR.

Curr Opin Neurol. 2005 Oct;18(5):604-10. Review.

PMID:
16155448
47.

Therapy for recurrent malignant glioma in adults.

Mrugala MM, Kesari S, Ramakrishna N, Wen PY.

Expert Rev Anticancer Ther. 2004 Oct;4(5):759-82. Review.

PMID:
15485312

Supplemental Content

Loading ...
Support Center